According to filings with the U.S. Securities and Exchange Commission, Reunion Neuroscience Management is raising up to $66,850,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Gregory Mayes played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Reunion Neuroscience Management
Reunion Neuroscience is committed to innovating therapeutic solutions to treat mental health conditions through the development of novel psychedelic compounds. NASDAQ:REUN. Reunion Neuroscience is a clinical stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression, adjustment disorder in cancer and other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

To learn more about Reunion Neuroscience Management, visit http://www.reunionneuro.com/

Contact:
Gregory Mayes, Chief Executive Officer
314-249-5289
https://www.linkedin.com/in/greg-mayes-82467911/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.